XOMA Corp


Friday’s Biotech News: Adamas Pharmaceuticals Inc (ADMS), XOMA Corp (XOMA), Kamada Ltd (KMDA)

A Peek Into Three Volatile Biotech Stocks: ADMS, XOMA, KMDA

Cowen Cautious on XOMA Corp (XOMA) Amid Clear Need for Funding After Q3 Print

XOMA Corp (NASDAQ:XOMA) shares are surging forward a sturdy 5% today after delivering its third-quarter financial results. Yet, considering the biotech firm’s pipeline …

Analysts Dive in on Two Falling Stocks: Imperva Inc (IMPV) and XOMA Corp (XOMA)

Analysts from BTIG and Webush are sharing insights on two falling stocks: Imperva Inc (NYSE:IMPV), whose shares are crashing close to 15% today, and …

Stock Update (NASDAQ:XOMA): XOMA Corp Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital Hyperinsulinism

XOMA Corp (NASDAQ:XOMA) announced the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted in principle the Company’s proposal to initiate a …

Wedbush Reduces Price Target On XOMA Corp (XOMA), But Remains Positive

XOMA Corp (NASDAQ:XOMA) recently released initial data from its single-dose trials for XOMA 358, the firm’s pipeline drug designed to treat rare endocrine …

Analysts Weigh In on Two Falling Biotech Stocks: Novavax, Inc. (NVAX) and XOMA Corp (XOMA)

Analysts are weighing in on Novavax, Inc. (NASDAQ:NVAX) and XOMA Corp (NASDAQ:XOMA), as shares of both companies fell sharply today due to various …

Stock Update (NASDAQ:XOMA): XOMA Corp Provides Update from Ongoing Phase 2 XOMA 358 Clinical Studies

XOMA Corp (NASDAQ:XOMA) provided an update on its ongoing XOMA 358 Phase 2 studies in patients with severe hypoglycemia due to congenital hyperinsulinism (CHI) …

Cowen Reiterates Neutral Stance on XOMA Corp (XOMA) as Pipeline Development Early and Uncertain

XOMA Corp (NASDAQ:XOMA) just ended its second quarter, and yet, all eyes are on the biotech company’s endocrinology portfolio, specifically XOMA 358, a …

Company Update (NASDAQ:XOMA): XOMA Corp Initiates Phase 2 Proof-of-Concept Study of XOMA 213

XOMA Corp (NASDAQ:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it has initiated its Phase 2 proof-of-concept study for …

Stock Update (NASDAQ:XOMA): XOMA Corp Reports First Quarter 2016 Operational Achievements and Financial Results

XOMA Corp (NASDAQ:XOMA), a leader in the discovery and development of therapeutic antibodies, announced recent operational achievements and financial results for the first quarter …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts